Tonix Pharmaceuticals Holding Corp. (NASDAQ: TNXP) has promoted Thomas Englese to the position of chief commercial officer, effective immediately. Englese, who previously served as executive vice president of commercial operations since September 2024, will retain oversight of sales, marketing, market access, and commercial operations for the company's key products, including TONMYA for fibromyalgia and its acute migraine treatments Zembrace SymTouch and Tosymra.
The promotion comes as Tonix focuses on solidifying its commercial infrastructure following the approval and launch of TONMYA, which represents the first new treatment for fibromyalgia in over 15 years. President and CEO Seth Lederman highlighted Englese's instrumental role in building the company's commercial organization and executing the TONMYA launch. Englese expressed the company's commitment to expanding patient access, growing its prescriber base, and driving sales as the launch broadens.
Tonix Pharmaceuticals is a fully integrated, commercial-stage biopharmaceutical company dedicated to addressing high unmet medical needs in central nervous system (CNS) and immunology. The company's flagship product, TONMYA (cyclobenzaprine HCl sublingual tablets 2.8mg), is being positioned as a significant advancement in fibromyalgia treatment. Beyond TONMYA, Tonix's CNS portfolio includes investigational candidates such as TNX-2900 for Prader-Willi syndrome, which is Phase 2 ready, and Phase 2 trials evaluating TONMYA's potential in major depressive disorder and acute stress disorder.
The company's immunology pipeline includes TNX-4800, a monoclonal antibody for Lyme disease prophylaxis, and TNX-1500, a third-generation CD40 ligand inhibitor for prevention of kidney transplant rejection. These product development candidates are investigational and have not yet been approved for any indication.
The promotion of Englese signals Tonix's commitment to strengthening its commercial capabilities as it seeks to maximize TONMYA's market potential. The company's recent launch of TONMYA and its focus on expanding access are critical to its growth strategy. For investors, this move underscores the company's emphasis on executing its commercial plan and delivering value from its approved products.
Englese's leadership will be pivotal as Tonix navigates the competitive landscape of fibromyalgia and migraine treatments. With a robust pipeline and a newly approved product, Tonix is positioning itself for sustained growth in the CNS market.
For more information about Tonix Pharmaceuticals and its recent developments, visit the company's newsroom at https://ibn.fm/TNXP.
